Targovax ASA - Information on the subsequent offering - Key date information
(Thomson Reuters ONE) -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY
OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE
SECURITIES DESCRIBED HEREIN.
Oslo, 9 June 2017: Reference is made to the stock exchange announcement made by
Targovax ASA ("Targovax" or the "Company") on 8 June 2017 regarding the
completed private placement (the "Private Placement") and the intention to carry
out a subsequent repair offering (the "Subsequent Offering") of up to 2,000,000
new shares in the Company (the "Offer Shares") for gross proceeds of up to NOK
40 million.
In accordance with the requirements of Oslo Børs, the following key information
is given with respect to the Subsequent Offering:
* Date of announcement of Subsequent Offering: 9 June 2017
* Last day including rights: 8 June 2017
* Ex-date: 9 June 2017
* Record date: 12 June 2017
* Date of approval: The Subsequent Offering is subject to approval at an
extraordinary general meeting to be held on 30 June 2017 (the "EGM").
* Maximum number of new shares: 2,000,000
* Subscription price: NOK 20
Other information:
The Subsequent Offering will be conditional upon (i) the resolution by the EGM
to issue the new shares in the Private Placement and the Offer Shares, (ii) the
completion of the Private Placement, and (iii) the Norwegian Financial
Supervisory Authority approving a combined prospectus for the listing of the New
Shares and the Subsequent Offering (the "Prospectus").
The Subsequent Offering will be based on the Prospectus. Shareholders in the
Company as of 8 June 2017, as registered in the VPS on 12 June 2017, who were
not allocated New Shares in the Private Placement and who are not resident in a
jurisdiction where such offering would be unlawful, or would (in jurisdictions
other than Norway) require any prospectus filing, registration or similar
action, will receive subscription rights.
The subscription period for the Subsequent Offering will commence shortly after
publication of the Prospectus (expected 3 July 2017). The subscription rights
will be listed and over-subscription and subscription without subscription
rights will be allowed in the Subsequent Offering. The subscription price in the
Subsequent Offering will be the same as in the Private Placement, i.e. NOK 20
per share.
ABG Sundal Collier ASA and DNB Markets, a part of DNB Bank ASA are acting as
Joint Lead Managers in connection with the Private Placement and the Subsequent
Offering.
For further information, please contact:
Erik Digman Wiklund, CFO
Phone: +47 413 33 536
Email: erik.wiklund(at)targovax.com
About Targovax
Arming the patient's immune system to fight cancer.
Targovax is a clinical stage company focused on developing and commercializing
novel immuno-oncology therapies to target, primarily, treatment-resistant solid
tumors. Immuno-oncology is currently one of the fastest growing therapeutic
fields in medicine.
The Company's development pipeline is based on two novel proprietary platforms:
The first platform, ONCOS, uses oncolytic viruses, an emerging class of
biological therapy. ONCOS exclusively uses an adenovirus that has been
engineered to be an immune activator that selectively target cancer cells. In
phase I it has shown to immune activate at lesional level which was associated
with clinical benefit. We expect proof of concept data for this platform in
2017 from a clinical trial of lead product ONCOS-102 in patients with refractory
malignant melanoma.
The second platform, TG peptides (TG), solely targets tumors that express
mutated forms of the RAS protein. Mutations to this protein are common in many
cancers and are known to drive aggressive disease progression and treatment
resistance. There is a high unmet medical need for therapies that are effective
against tumors that express these mutations. The TG platform's therapeutic
potential stems from its ability to enable a patient's immune system to identify
and then destroy tumors bearing any RAS mutations. In early 2017, key proof of
concept data for the TG platform from a clinical trial of TG01 in resected
pancreatic cancer patients showed encouraging overall survival and will give
guidance for the future clinical development of this platform.
Targovax's development pipeline has three novel therapeutic candidates in
clinical development covering six indications.
Both platforms are protected by an extensive portfolio of IP and know-how and
have the potential to yield multiple product candidates in a cost-effective
manner. Additionally, we have other products in early stages of development.
In July 2016, the Company listed its shares on Oslo Axess. In March 2017, the
shares were upgraded to Oslo Børs, the main Oslo Stock Exchange.
IMPORTANT NOTICE:
This announcement is not and does not form a part of any offer for sale of
securities.
Copies of this announcement are not being made and may not be distributed or
sent into the United States, Australia, Canada, Japan or any other jurisdiction
in which such distribution would be unlawful or would require registration or
other measures.
The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and accordingly may not be offered or sold in the United States absent
registration or an exemption from the registration requirements of the
Securities Act and in accordance with applicable U.S. state securities laws. The
Company does not intend to register any part of the offering in the United
States or to conduct a public offering of securities in the United States. Any
offering of the securities referred to in this announcement will be made by
means of a prospectus.
This announcement is not a prospectus for the purposes of Directive 2003/71/EC
(together with any applicable implementing measures in any Member State, the
"Prospectus Directive"). Investors should not subscribe for any securities
referred to in this announcement except on the basis of information contained in
the aforementioned prospectus. In any EEA Member State other than Norway that
has implemented the Prospectus Directive, this communication is only addressed
to and is only directed at qualified investors in that Member State within the
meaning of the Prospectus Directive, i.e., only to investors who can receive the
offer without an approved prospectus in such EEA Member State.
This communication is only being distributed to and is only directed at persons
in the United Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities,
and other persons to whom this announcement may lawfully be communicated,
falling within Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as "relevant persons"). This communication must not be acted
on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this communication relates is available only to
relevant persons and will be engaged in only with relevant persons. Persons
distributing this communication must satisfy themselves that it is lawful to do
so.
The information, opinions and forward-looking statements contained in this
announcement speak only as at its date, and are subject to change without
notice.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Rainy Mountain Royalty Corp: Phase 1 Drilling on Brunswick Gold Exploration Property Completed and Numerous Gold Settings ExposedDatum: 09.06.2017 - 07:52 Uhr
Sprache: Deutsch
News-ID 547134
Anzahl Zeichen: 9330
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 254 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax ASA - Information on the subsequent offering - Key date information"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
